BRAF and melanoma: Taken together, the preclinical efficacy in the AGK::BRAF fusion melanoma model, and the fact that tovorafenib has been approved for relapsed/refractory pLGGs, supports tissue agnostic activity for tovorafenib in tumors harboring BRAF fusions or rearrangements.